Evaluation of the Effect of Dextran Sulphate on Anti-Xa Activities Measured

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

164 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-16

Study Completion Date

2021-01-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The measurement of anti-Xa activity is classically used for the dose adjustement of unfractionated heparin (UFH) treatment and to monitor reversal of UFH by protamine during cardiac surgery with cardiopulmonary bypass (CPB). Three categories of reagents are currently available in France for the measurement of anti-Xa activity: antithrombin-containing reagents (very little used), antithrombin-free reagents and antithrombin-free reagents with dextran sulphate. Significant differences in anti-Xa results based on the reagents used were described, particularly after protamine neutralization in CPB. Indeed, dextran sulphate, contained in some reagents, could dissociate the heparin/protamine complex contributing to the higher levels of anti-Xa with these reagents. The differences observed in these patients are likely related to the presence of platelet factor 4 (PF4) in the samples from either PF4 present in vivo in patients or released in vitro after blood collection. These differences may lead to different therapeutic attitudes, including the re-administration of protamine to neutralize heparin at the end of CBP

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

NCT02329327

Bleeding

COMPLETED PHASE3

LMWH-VTE Prophylaxis for Survivors of Acute Ischemic Stroke- Assessment of Standard Dosing Regimen

NCT03593291

Stroke

UNKNOWN

Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

NCT03311984

Critically Ill Anti-Xa

UNKNOWN

HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT

NCT07302620

Thromboembolic Disease

RECRUITING

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin

NCT02970032

Deep-Venous Thrombosis Pulmonary Embolism Venous Thromboembolism

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Any hospitalized patient receiving UFH in the intensive, cardiac surgery and medicine departments of the participating centres will be offered the study by investigator. It will be included in the study after validation of the selection criteria and after collecting its non-opposition. This participation will not change the medical care of the participants.

Patients will be divided into four groups:

* Group 1: patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine.
* Group 2: patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.
* Group 3: hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).

Group 4: patients hospitalized in a medical non-intensive care ward.

The response to heparin treatment varies considerably depending on the clinical situation. The results found in one indication are not transposable to another indication. The 4 patient groups will provide a comprehensive response to situations in which heparin is used.

For each patient, during the usual follow-up of anti-Xa activity, and only once per patient, 3 to 4 additional blood tubes - 1 citrate tube (0.109 M) of 5 mL or 2 citrate tubes of 3 mL and 2 tubes CTAD (Citrate-Theophylline, Adenosine, Dipyrioledam) of 3 mL - will be taken during a blood test carried out in common practice. Thus, no additional invasive gestures are added by this search. CTAD contains, in addition to citrate, a platelet activation inhibitor and thus limits the in-vitro activation of platelets and thus the release of PF4.

Blood samples will be handle according to the usual procedures of each centre. All plasma will be aliquoted and stored at -80oC, until the end of inclusions in the hematology laboratories of each center.

At the end of the inclusion period, the aliquotes will be sent to the hematology laboratories of the Necker University Hospital and the University Hospital of Rennes for centralized testing.

The measurement of anti-Xa activities will be carried out on frozen-defrosted citrate and CTAD plasma with with 4 reagents:

* STA-Liquid anti-Xa (STAGO) (not containing dextran)
* Biophen Heparin LRT (Hyphen) (containing dextran)
* Berichrom (Siemens) with dextran
* Berichrom (Siemens) without dextran

The dosage of platelet factor 4 and beta-TG will be performed on frozen-defrosted plasma with CTAD with asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unfractionated Heparin Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine

measurement of anti-Xa activities

Intervention Type BIOLOGICAL

The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents

* STA-Liquid anti-Xa (STAGO) (not containing dextran)
* Biophen Heparin LRT (Hyphen) (reactive containing dextran)
* Berichrom (Siemens) with dextran
* Berichrom (Siemens) without dextran

The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.

Group 2

patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.

measurement of anti-Xa activities

Intervention Type BIOLOGICAL

The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents

* STA-Liquid anti-Xa (STAGO) (not containing dextran)
* Biophen Heparin LRT (Hyphen) (reactive containing dextran)
* Berichrom (Siemens) with dextran
* Berichrom (Siemens) without dextran

The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.

Group 3

hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).

measurement of anti-Xa activities

Intervention Type BIOLOGICAL

The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents

* STA-Liquid anti-Xa (STAGO) (not containing dextran)
* Biophen Heparin LRT (Hyphen) (reactive containing dextran)
* Berichrom (Siemens) with dextran
* Berichrom (Siemens) without dextran

The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.

Group 4

patients hospitalized in a medical non-intensive care ward.

measurement of anti-Xa activities

Intervention Type BIOLOGICAL

The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents

* STA-Liquid anti-Xa (STAGO) (not containing dextran)
* Biophen Heparin LRT (Hyphen) (reactive containing dextran)
* Berichrom (Siemens) with dextran
* Berichrom (Siemens) without dextran

The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

measurement of anti-Xa activities

The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents

* STA-Liquid anti-Xa (STAGO) (not containing dextran)
* Biophen Heparin LRT (Hyphen) (reactive containing dextran)
* Berichrom (Siemens) with dextran
* Berichrom (Siemens) without dextran

The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

dosage of platelet factor 4 and of the beta-TG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over the age of 18;
* Hospitalized patients to receive UFH;
* No patient opposition.

Patients will be divided into four groups:

* Group 1: patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine.
* Group 2: patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.
* Group 3: hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).

Group 4: patients hospitalized in a medical non-intensive care ward..

Exclusion Criteria

* pregnant or lactating women;
* adults subject to legal protection (safeguarding of justice, guardianship, guardianship), persons deprived of their liberty.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No